Broad immune and hematopoietic cell populations

Broad immune and hematopoietic cell populations encompass the entire lineage of cells originating from hematopoietic stem cells in the bone marrow, including both myeloid and lymphoid branches. This group includes essential immune effectors such as T cells, B cells, natural killer cells, monocytes, and granulocytes, as well as erythrocytes and megakaryocytes (StatPearls, 2023). These populations are fundamental to host defense, systemic homeostasis, and tissue repair, but they also represent the primary site of pathology in hematologic malignancies and autoimmune disorders (NIH, 2022). While these populations are frequently the focus of therapeutic intervention, the term itself does not refer to a single molecular target; rather, it describes a cellular compartment affected by various drugs. In drug development, therapies are typically designed to target specific proteins within these cells, such as kinases or surface receptors, to modulate the overall population's behavior. Monitoring the health and composition of these cell populations is a critical safety requirement for many systemic therapies to avoid life-threatening complications like severe myelosuppression.

Other names

Hematopoietic systemImmune system cellsBlood cellsLeukocytes and precursorsHematopoietic lineage

Not applicable as a single mechanism; drugs affecting these populations act through diverse molecular pathways including DNA alkylation, cell surface receptor binding (e.g., CD20), or cytokine receptor agonism.